GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sinocare 300298.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

18.75

-1.57%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥4.66bn

FY2016FY2025

Net income

CN¥92.6m

FY2016FY2025

Free cash flow

CN¥406.3m

FY2016FY2025

Shareholders' equity

CN¥3.11bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥4.66bnCN¥4.44bnCN¥4.06bnCN¥3.95bnCN¥2.36bnCN¥2.02bnCN¥1.78bnCN¥1.55bnCN¥1.03bnCN¥795.8m
Gross profitCN¥2.27bnCN¥2.42bnCN¥2.15bnCN¥2.05bnCN¥1.39bnCN¥1.30bnCN¥1.15bnCN¥987.0mCN¥697.2mCN¥509.9m
Research and developmentCN¥274.6mCN¥375.0mCN¥356.4mCN¥306.3mCN¥182.4mCN¥182.5mCN¥161.3mCN¥128.8mCN¥74.0mCN¥52.0m
Operating incomeCN¥96.6mCN¥399.0mCN¥275.0mCN¥391.0mCN¥139.3mCN¥359.5mCN¥276.4mCN¥318.2mCN¥297.4mCN¥72.8m
Net incomeCN¥92.6mCN¥326.3mCN¥284.4mCN¥446.5mCN¥107.6mCN¥186.9mCN¥250.7mCN¥310.4mCN¥258.0mCN¥115.2m
Diluted earnings per share0.170.590.510.800.190.330.440.550.490.24

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥5.96bnCN¥6.10bnCN¥5.93bnCN¥4.62bnCN¥4.15bnCN¥3.90bnCN¥3.28bnCN¥3.00bnCN¥1.66bnCN¥1.47bn
Cash and short-term investments—CN¥954.7mCN¥816.0mCN¥843.5mCN¥932.4mCN¥1.14bnCN¥566.0mCN¥662.8mCN¥323.4mCN¥215.8m
Total liabilitiesCN¥2.52bnCN¥2.33bnCN¥2.46bnCN¥1.47bnCN¥1.36bnCN¥1.15bnCN¥632.6mCN¥377.0mCN¥273.2mCN¥195.7m
DebtCN¥201.7mCN¥597.3mCN¥982.3mCN¥524.4mCN¥655.0mCN¥554.3mCN¥162.0mCN¥2.6mCN¥14.9m—
Shareholders' equityCN¥3.11bnCN¥3.36bnCN¥3.08bnCN¥3.12bnCN¥2.79bnCN¥2.73bnCN¥2.65bnCN¥2.62bnCN¥1.39bnCN¥1.28bn
Shares outstanding551m554m556m555m553m568m565m565m529m487m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥605.1mCN¥631.3mCN¥735.1mCN¥474.4mCN¥480.0mCN¥504.6mCN¥522.8mCN¥319.3mCN¥243.9mCN¥203.4m
Capital spending−CN¥198.9m−CN¥186.7m−CN¥346.6m−CN¥311.2m−CN¥403.8m−CN¥275.6m−CN¥422.0m−CN¥242.4m−CN¥98.7m−CN¥55.5m
Free cash flowCN¥406.3mCN¥444.6mCN¥388.5mCN¥163.2mCN¥76.2mCN¥229.1mCN¥100.8mCN¥76.9mCN¥145.2mCN¥147.9m
Dividends paid−CN¥135.1m−CN¥132.2m−CN¥111.5m−CN¥111.6m−CN¥113.1m−CN¥167.8m−CN¥169.6m−CN¥142.1m−CN¥121.7m−CN¥90.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.30bnCN¥1.24bnCN¥1.21bnCN¥1.19bnCN¥1.22bnCN¥1.04bnCN¥1.26bnCN¥1.05bn
Gross profitCN¥698.7mCN¥650.8mCN¥582.0mCN¥515.0mCN¥669.4mCN¥507.2mCN¥659.8mCN¥585.1m
Operating incomeCN¥144.0mCN¥148.1mCN¥92.4m−CN¥22.2mCN¥99.3mCN¥93.1mCN¥77.8mCN¥65.7m
Net incomeCN¥123.7mCN¥97.7m−CN¥118.4mCN¥30.3mCN¥108.5mCN¥72.1mCN¥70.9mCN¥57.9m
Diluted earnings per share0.220.18-0.210.060.200.130.130.10
Cash from operations———CN¥264.0mCN¥76.0mCN¥197.0mCN¥228.0mCN¥175.0m
Capital spending−CN¥33.0m−CN¥38.0m−CN¥43.0m−CN¥28.0m−CN¥77.0m−CN¥49.0m−CN¥20.0m−CN¥17.0m
Free cash flow———CN¥236.0m−CN¥1.0mCN¥148.0mCN¥208.0mCN¥158.0m
Total assetsCN¥5.95bnCN¥5.79bnCN¥5.96bnCN¥6.25bnCN¥6.03bnCN¥5.99bnCN¥6.10bnCN¥5.93bn
Cash and short-term investments———CN¥1.07bnCN¥808.2mCN¥979.7mCN¥954.7mCN¥845.4m
DebtCN¥360.8mCN¥273.6mCN¥201.7mCN¥286.6mCN¥658.8mCN¥696.6mCN¥586.2mCN¥591.0m
Shareholders' equityCN¥3.08bnCN¥3.10bnCN¥3.11bnCN¥3.32bnCN¥3.34bnCN¥3.43bnCN¥3.36bnCN¥3.18bn

Financial ratios

Data as of 6 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin48.7%54.4%53.0%52.0%58.7%64.5%
Operating margin2.4%9.8%10.1%10.6%10.9%17.8%
Net margin2.0%7.3%7.0%11.3%4.6%9.3%
Return on equity3.0%9.7%9.2%14.3%3.9%6.8%
Return on assets1.6%5.4%4.8%9.7%2.6%4.8%
Free cash flow yield9.0%9.1%11.9%8.7%9.8%8.4%
Revenue growth4.9%9.5%2.7%67.4%17.2%13.3%
Earnings growth-71.6%14.7%-36.3%315.1%-42.4%-25.4%
Current ratio1.14x1.41x1.62x2.06x2.21x3.23x
Debt to equity0.06x0.17x0.34x0.21x0.23x0.20x
Equity ratio52.2%55.1%51.9%67.6%67.1%70.2%
Interest coverage2.90x8.21x6.18x5.81x7.61x19.39x
R&D as a share of sales5.9%8.4%8.8%7.7%7.7%9.1%
Buybacks as a share of market value0.6%0.4%-0.1%-0.4%2.7%-0.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.6%18.2%21.9%
Operating income-37.2%-23.1%-3.5%
Net income-40.8%-13.1%-4.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin51.5%52.0%53.9%56.2%
Operating margin5.4%6.8%7.7%10.1%
Net margin4.6%6.7%6.7%9.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings101.843.859.441.9153.8108.933.819.333.953.3
Price to sales2.03.24.24.77.010.14.83.98.57.7

Dividends and splits

Per share, in the currency the company pays

Paid for 14 years. Last went ex-dividend on 13 Jun 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.220.200.200.200.200.300.300.25
  • 6-for-5 split · 16 Jul 2018
  • 6-for-5 split · 19 May 2017
  • 13-for-10 split · 11 Mar 2016
  • 1.299-for-1 split · 18 May 2015
  • 3-for-2 split · 13 May 2014
  • 3-for-2 split · 3 Apr 2013

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.